Trusted life sciences real estate that serves your industry's needs

Life sciences real estate services: sequencing your real estate needs

Life sciences real estate requirements are technically complex, capital intensive, and atypical for real estate service providers whose primary focus is office or warehouse space. Time-to-market and funding are crucial factors in driving innovation and successful new pharmaceutical product launches, which, in turn, require laboratories, vivaria, pilot plants, and manufacturing facilities. Our life sciences real estate specialists understand the pharmaceutical product life cycle as well as the technical complexities that can create significant budgetary and scheduling risks. We’ve successfully addressed the risks that surround life sciences real estate decision-making throughout all phases of the product life cycle and across all technical aspects of planning, designing, engineering, and constructing any type of life science space.

Connect with my local life sciences real estate advisor

The centerpiece of our approach is how we integrate your technical and financial requirements into the life sciences real estate negotiation process, ensuring these requirements are incorporated accurately into the transaction documents. This fully integrated process enables our team to develop innovative strategies with credible budgets and schedules at early transaction stages, providing clients with the facts needed to make more fully informed decisions.

This transparent, risk averse, “cradle-to-grave” model creates seamless continuity and allows complete flexibility, maximizing the efficacy of our client’s internal resources on either a portfolio or transactional basis.

Life sciences real estate services include:

Strategic Real Estate Planning
Site Selection
Pre-Lease Budgeting and Scheduling
Lease Negotiation
Site Evaluation Due Diligence Oversight
Consultant Team Selection, Engagement and Oversight
Post-Lease Project Management
Construction Management

U.S. life sciences market H1 2024 insights

The lab/R&D market showed signs of revitalization during the first half of 2024 despite record-high availability and stagnant occupier demand. Most notably, funding into the life sciences sector received a large boost from venture capital investment, public markets, and the U.S. government which is expected to increase leasing activity in the second half of the year and in 2025. Moreover, construction starts for lab buildings came to a near halt, allowing the market time to absorb the newer product, which accounts for most of the lab/R&D availability.

EXPLORE H1 2024 LIFE SCIENCES MARKET DATA

Bay Area life sciences market update

The life science market experienced a significant boom amid the pandemic, but the terrain has swiftly evolved. The diminished appetite for high-risk life science research and development has led to a significant decrease of funding for the life science industry. It is crucial for both owners and occupiers to stay light on their feet to navigate and capitalize on today's rapidly changing environment.

DOWNLOAD THE Q2 2024 BAY AREA LIFE SCIENCES MARKET REPORT

NIH funding into U.S. life science sector on pace for another record-setting year

With funding allocations from the National Institute of Health shifting in 2024, how is the U.S. life science and healthcare sector affected?

Learn more

graph of NIH funding amount vs. the percent distributed toward lab/R&D occupiers from 2014 to 2024 in the life science and healthcare sector

Which U.S. markets are seeing the greatest surge in healthcare and lab employee foot traffic?

Explore the varying levels of employee foot traffic across key life science facilities across the U.S. over the course of a year.

Learn more

graph of employee visitations for biotech, life science, pharma, and healthcare assets from June 2023 to June 2024 in the top U.S. life science markets

Capitalizing on resurgence: U.S. life science IPOs poised to spark leasing demand in 2024 and 2025

Indicators point to a potential increase in life science IPOs in 2024, which could lead to an uptick in leasing activity.

Learn more

graph of number of completed and announced life science IPOs compared to leasing activity in the U.S. from 2015 to 2024

Subscribe to Avison Young email communications for news, listing information, research reports and to learn more about our life sciences real estate services.

Life sciences commercial real estate news and updates

Life sciences industry overview

Driven by an aging population, steady funding sources, and an urgent need to discover and develop vaccines and treatments for COVID-19, growth in life sciences industries shows no sign of slowing down. Unique location and space use requirements have made the sector resilient, drawing the attention of real estate investors in need of the services of life science commercial real estate specialists.

Learn more